But Millennium (nasdaq: MLNM - news - people ), a leading genomics firm, bought COR Therapeutics (nasdaq: CORR - news - people ) only a few weeks before that big deal went down, for similar reasons: Millennium wanted COR's cardiovascular drug, Integrilin.